GEN News Highlights

New Formulation for Nexium Receives Authorization

(Page
1
of
1)

AstraZeneca’s Nexium For Delayed-Release Oral Suspension has been approved for the treatment of GERD, including symptomatic gastroesophageal reflux disease, healing and maintenance of healing of erosive esophagitis, and risk reduction of NSAID-associated gastric ulcers. AstraZeneca expects that the new formulation will be available in the first quarter of 2007.

Each packet of Nexium For Delayed-Release Oral Suspension contains either 20 mg or 40 mg of esomeprazole, the active ingredient used in Nexium Delayed-Release Capsules, explains AstraZeneca. The esomeprazole granules and inactive granules used in this formulation are mixed with water to form a suspension and are given by oral, nasogastric, or gastric administration.

"Some patients with acid-related diseases have difficulties swallowing their oral medication when it is a solid pill," remarks Doug Levine, M.D., executive director, clinical development leader for Nexium. "This new prescription option to swallow an oral suspension of Nexium or to have it administered via a stomach tube provides these patients with an alternative method of administration that they can take instead of the Nexium capsule."

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.1%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.